Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022 SITC Annual Meeting

PR Newswire

Acepodia Congratulates Laureates of the 2022 Nobel Prize in Chemistry and Shares the Excitement to Translate Click Chemistry into a New Class of Investigational Therapies

PR Newswire

Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin's Lymphoma

PR Newswire

Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies

GlobeNewswire

Acepodia Presents Preclinical Data on its gamma delta T cell Therapy Candidate ACE1831 at 2022 AACR Meeting

Acepodia Announces Expansion of Board of Directors and Scientific Advisory Board

GlobeNewswire

Acepodia Strengthens Board of Directors and Scientific Advisory Board with Key Appointments

GlobeNewswire

Natural Killer Cell Therapy Well Tolerated in Solid Tumors

GeneTherapyLive

Developing Cell Therapies for Solid Tumors and Hematologic Malignancies

GeneTherapyLive

ESMO shifts the HER2 antibody landscape

BioCentury

Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors

GlobeNewswire

Acepodia uncorks a very early win for its antibody-natural killer cell conjugates in HER2 tumors

Endpoints News